Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

Phase 1, Investigator-Blind, Subject-Blind, Sponsor-Open, Placebo-Controlled, Two-Week, Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP-690,550

This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.

Study Overview

• Status: Completed
• Conditions: Psoriasis; Immunomodulation
• Intervention / Treatment: Drug: tofacitinib; Drug: tofacitinib; Drug: tofacitinib; Drug: tofacitinib; Drug: tofacitinib; Drug: tofacitinib

• Study Type: Interventional
• Enrollment (Actual): 59
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72202
      • Pfizer Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and/or female subjects between the ages of 18 and 65 years, inclusive, with active psoriasis lesion(s).
• Subjects should be healthy with the exception of psoriasis, where healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination. Blood pressure must be < 140/89. Body Mass Index (BMI) between 18-36 kg/m2, inclusive; and a total body weight >50 kg (110 lbs)
• The following laboratory variables must be no more than 10% below the lower limit of the normal reference range: RBC, hemoglobin, hematocrit, WBC, absolute neutrophil count. The absolute lymphocyte count must be greater than or equal to the lower limit of the reference range. Values for AST, ALT, bilirubin and alkaline phosphatase must be no more than 10% above the upper limit of the normal reference range. Values for total cholesterol and LDL must be no more than 20% above the upper limit of the normal reference range except for subjects being treated for hyperlipidemia. Normal glomerular filtration rate (> 80 mL/min).

Exclusion Criteria:

• Subjects with evidence or history of clinically significant hematological, renal, urological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic disorder.
• Subjects with controlled essential hypertension and/or hyperlipidemia may be eligible for the study provided that any medications that are administered.
• Screening 12-lead ECG demonstrating at least one of the following: heart rate > 100 bpm, QRS >120 msec, QTc > 430 msec (males), QTc > 450 msec (females) or PR > 220 msec.
• Abnormal chest radiographs including, but not limited to, evidence of past or present tuberculosis infection. History of tuberculosis without treatment and/or positive tuberculin reaction without known vaccination with BCG.
• Subjects with a history of tumors with the exception of adequately treated basal cell carcinoma of the skin.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 5 mg BID; 5 mg BID for 13 days and once on Day 14	Drug: tofacitinib; 5 mg BID For 13 days and once on Day 14; Drug: tofacitinib; 10 mg BID for 13 days and once on Day 14*; Drug: tofacitinib; 20 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 30 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 60 mg tablet once a day (QD) for 14 days; Drug: tofacitinib; 50 mg tablets two times a day (BID) for 13 days and once on day 14
Experimental: 10 mg BID; 10 mg BID for13 days and once on Day 14*	Drug: tofacitinib; 5 mg BID For 13 days and once on Day 14; Drug: tofacitinib; 10 mg BID for 13 days and once on Day 14*; Drug: tofacitinib; 20 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 30 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 60 mg tablet once a day (QD) for 14 days; Drug: tofacitinib; 50 mg tablets two times a day (BID) for 13 days and once on day 14
Experimental: 20 mg BID; 20 mg BID for 13 days and once on Day 14	Drug: tofacitinib; 5 mg BID For 13 days and once on Day 14; Drug: tofacitinib; 10 mg BID for 13 days and once on Day 14*; Drug: tofacitinib; 20 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 30 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 60 mg tablet once a day (QD) for 14 days; Drug: tofacitinib; 50 mg tablets two times a day (BID) for 13 days and once on day 14
Experimental: 30 mg BID; 30 mg BID for 13 days and once on Day 14	Drug: tofacitinib; 5 mg BID For 13 days and once on Day 14; Drug: tofacitinib; 10 mg BID for 13 days and once on Day 14*; Drug: tofacitinib; 20 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 30 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 60 mg tablet once a day (QD) for 14 days; Drug: tofacitinib; 50 mg tablets two times a day (BID) for 13 days and once on day 14
Experimental: 60 mg QD; 60 mg QD for 14 days	Drug: tofacitinib; 5 mg BID For 13 days and once on Day 14; Drug: tofacitinib; 10 mg BID for 13 days and once on Day 14*; Drug: tofacitinib; 20 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 30 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 60 mg tablet once a day (QD) for 14 days; Drug: tofacitinib; 50 mg tablets two times a day (BID) for 13 days and once on day 14
Experimental: 50 mg BID; 50 mg BID x 13 days and once on day 14	Drug: tofacitinib; 5 mg BID For 13 days and once on Day 14; Drug: tofacitinib; 10 mg BID for 13 days and once on Day 14*; Drug: tofacitinib; 20 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 30 mg BID for 13 days and once on Day 14; Drug: tofacitinib; 60 mg tablet once a day (QD) for 14 days; Drug: tofacitinib; 50 mg tablets two times a day (BID) for 13 days and once on day 14

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo.	8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0.	Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.	12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14
Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (<) 60 msec(borderline) and greater than or equal to (>=) 60 msec (prolonged) were summarized.	1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21
Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc >=500 msec were reported.	1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	AUCtau = area under the curve from time zero to end of dosing interval.	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	AUCtau = area under the curve from time zero to end of dosing interval.	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Maximum Observed Plasma Concentration (Cmax) at Day 1		0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Maximum Observed Plasma Concentration (Cmax) at Day 14		0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1		0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14		0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Accumulation Ratio (R0)	Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1.	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, 1 hr post-dose on Day 1
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, hr 0 on Day 2
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, hr 0 on Day 4
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, hr 0 on Day 7
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, hr 0 on Day 10
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline; hr 0, 8 hr post-dose on Day 14
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, Hour 0 on Day 18
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, hr 0 on Day 21
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, hr 0 on Day 28
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.	Baseline, hr 0 on Day 42
Change From Baseline in Immune Cell Function at Day 14	The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, >= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy.	Baseline (Within 7 days prior to Day 1), Day 14
Change From Baseline in Reticulocyte Count at Day 2	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 2
Change From Baseline in Reticulocyte Count at Day 4	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 4
Change From Baseline in Reticulocyte Count at Day 7	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 7
Change From Baseline in Reticulocyte Count at Day 10	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 10
Change From Baseline in Reticulocyte Count at Day 15	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 15
Change From Baseline in Reticulocyte Count at Day 21	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 21
Change From Baseline in Reticulocyte Count at Day 28	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 28
Change From Baseline in Reticulocyte Count at Day 42	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.	Baseline (Within 7 days prior to Day 1), Day 42
Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function		Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42
Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)	EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured.	Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity.	Baseline (Within 7 days prior to Day 1) up to Day 14
Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis).	Baseline (Within 7 days prior to Day 1) up to Day 14
Gene Expression in Psoriatic Plaque Biopsies	Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC.	Day 14
Immunohistochemistry From Psoriatic Plaque Biopsies	Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo.	Baseline (within 7 days prior to Day 1), Day 14
Number of Participants With Keratin 16 (K16) Expression	Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes.	Baseline (within 7 days prior to Day 1) up to Day 14
Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression	Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes.	Baseline (within 7 days prior to Day 1) up to Day 14
Gene Expression in Peripheral Blood	Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 [SF5]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA).	Day 14

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start: November 1, 2002
• Primary Completion (Actual): April 1, 2004
• Study Completion (Actual): April 1, 2004

Study Registration Dates

• First Submitted: November 26, 2012
• First Submitted That Met QC Criteria: November 26, 2012
• First Posted (Estimate): November 29, 2012

Study Record Updates

• Last Update Posted (Estimate): February 20, 2013
• Last Update Submitted That Met QC Criteria: January 16, 2013
• Last Verified: January 1, 2013

More Information

Terms related to this study

• Keywords: Psoriasis; PASI; plaques; immunomodulation; skin biopsy
• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; Tofacitinib
• Other Study ID Numbers: A3921003